Fig 1: Met induced pyroptosis in HepG2 and Huh7 cells. (A) Morphologic observation of the HepG2 and Huh7 cell lines after treatment with different concentrations of Met. (B, C) Western blot was performed to evaluate the expression level of pyroptosis-related proteins NLRP3, cleaved-caspase1, IL-1ß, IL-18, and GSDMD after Met treatment. (D, E) Western blot was performed to evaluate the expression level of pyroptosis-related proteins NLRP3, cleaved-caspase1, IL-1ß, IL-18, and GSDMD after co-treatment with different concentrations of Met and si-FOXO3. (F) MTT was used to evaluate the cell viability of HepG2 and Huh7 cells. *P<0.05 vs control group, #P<0.05 vs Met+vehicle group.
Fig 2: NF-κB signaling pathway was involved in the ameliorative effect of NLRP3-KO on lung injury. (a) Representative western blot bands for p65, p-p65, ASC, CL-Cas1, IL-1β, and IL-18. (b ~ f) Quantification of ASC/GAPDH, CL-Cas1/GAPDH, IL-1β/GAPDH, IL-18/GAPDH, and p-p65/GAPDH, respectively. The data are presented as the mean ± SEM. n = 5 per group. AP < 0.05 vs. Sham; BP < 0.05 vs. WT.
Fig 3: The circ_0004951/miR-93-5p/ NLRP3 axis regulates HG-induced pyroptosis in HK2. LDH release in each group (A). Caspase-1 activity in each group (B). ELISA results showing expression levels of IL-1ß and IL-18 in each group (C,D). HG, high glucose; HK2, human renal tubular epithelial cell line; LDH, lactate dehydrogenase. Values are expressed as mean ± SD. *p < 0.05 vs. control.
Fig 4: Administration of Rux reduced NLRP3 inflammasome activation in HT22 cells after OGD/R. (A) Representative western blots showing NLRP3, ASC, CL-caspase-1, IL-1ß and IL-18 at the protein level. (B–F) Quantification results of NLRP3, ASC, CL-caspase-1, IL-1ß and IL-18 expression at the protein level. Means ± SD. n = 5/group. aP < 0.01 versus control; bP < 0.05 versus OGD/R + vehicle; cP < 0.05 versus OGD/R + LPS.
Fig 5: Serum levels of IL-1b and IL-18 in systemic lupus erythematosus (SLE) patients as examined by ELISA. Serum IL-1b and IL-18 levels were higher in the SLE group than in the healthy control group, and the expression of IL-1b and IL-18 was decreased after treatment (continuous methylprednisolone treatment; 40 mg/day for 2 weeks). SLE + BT: SLE patients before treatment; SLE + AT: SLE patients after treatment; IL-1b (a); IL-18 (b).*p < 0.05, #p > 0.05, as determined by the t-test
Supplier Page from Abcam for Anti-IL-18 antibody [EPR19954]